British drug maker AstraZeneca is cooperating with government regulators in investigating a manufacturing error of an experimental COVID-19 vaccine. The pharmaceutical company and Oxford University have admitted that a lower dosage of the vaccine performed better than a full dosage, according to a spokesman who spoke after AstraZeneca’s CEO said a further global trial was likely. The statement comes as the company prepared to provide a temporary supply of the drug ahead of its plans to distribute 4 million doses of the vaccine by the year’s end. Meanwhile, Australia’s second-largest state, Victoria, has recorded no new coronavirus infections or deaths in the past 28 days, health officials said Friday. The state did not have any active cases after the last COVID-19 patient was discharged from the hospital Monday. While Victoria has achieved the 28-day benchmark, widely accepted by health experts as eliminating the virus from the community, cases of the coronavirus infections have been detected in other parts of the country. In Latin America, Brazilian President Jair Bolsonaro said Thursday he would refuse a coronavirus vaccine, the most recent of his vaccine-skeptic statements. “I’m telling you, I’m not going to take it. It’s my right,” he said in remarks aired… Read full this story
- Reality bites for Putin's much-hyped Covid-19 vaccine, as concerns over efficacy and safety linger
- Los Angeles Issues Stay-at-Home Order to Curb COVID
- When will a coronavirus vaccine really be ready?
British AstraZeneca to Conduct Another Trial Before Widely Distributing COVID-19 Vaccine have 244 words, post on www.voanews.com at November 28, 2020. This is cached page on The Best Articles. If you want remove this page, please contact us.